Legend Biotech said CEO Ying Huang resigned with no permanent replacement named, appointing Alan Bash as interim CEO and initiating a search process for a successor. The company said Huang’s resignation was not linked to disagreements on operations, policies, or financial reporting controls, and Huang will remain as an advisor through August. Bash, currently president of Legend’s Carvykti business, takes over as Legend navigates commercial execution and competitive pressure in multiple myeloma. The leadership shift also comes against a backdrop of geopolitical risk concerns related to Legend’s China ties and a history of leadership disputes earlier in the company’s lifecycle. Operational continuity is the stated priority, but the governance change is likely to influence investor sentiment and expectations around regulatory and commercial momentum for Carvykti. For biotech boards, the case highlights how quickly leadership transitions can intersect with market scrutiny when a single franchise therapy sits at the center of growth narratives.